Results 31 to 40 of about 749,314 (382)

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

New England Journal of Medicine, 2017
Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an oral multitargeted kinase inhibitor that is active in patients with a FLT3 ...
R. Stone, S. Mandrekar, B. Sanford, K. Laumann, S. Geyer, C. Bloomfield, C. Thiede, T. Prior, K. Döhner, G. Marcucci, F. Lo‐Coco, R. Klisovic, A. Wei, J. Sierra, M. Sanz, J. Brandwein, T. D. de Witte, D. Niederwieser, F. Appelbaum, B. Medeiros, M. Tallman, J. Krauter, R. Schlenk, A. Ganser, H. Serve, G. Ehninger, S. Amadori, R. Larson, H. Döhner   +28 more
semanticscholar   +1 more source

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

American journal of hematology/oncology, 2020
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults.
E. Jabbour, H. Kantarjian
semanticscholar   +1 more source

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

Haematologica, 2010
Background C-type lectin-like molecule-1 is a transmembrane receptor expressed on myeloid cells, acute myeloid leukemia blasts and leukemic stem cells.
Xiaoxian Zhao, Shweta Singh, Cecile Pardoux, Jingsong Zhao, Eric D. Hsi, Arie Abo, Wouter Korver   +6 more
doaj   +1 more source

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

New England Journal of Medicine, 2001
BACKGROUND BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment ...
B. Druker, M. Talpaz, D. Resta, B. Peng, E. Buchdunger, J. Ford, N. Lydon, H. Kantarjian, R. Capdeville, Sayuri Ohno-Jones, C. Sawyers   +10 more
semanticscholar   +1 more source

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications, 2020
Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection. Precise characterization of clonal architecture is essential to understand the evolutionary history of tumor development and its association with treatment ...
Kiyomi Morita, Kiyomi Morita, Feng Wang, Katharina Jahn, Katharina Jahn, T. Hu, Tomoyuki Tanaka, Yuya Sasaki, Jack Kuipers, Jack Kuipers, S. Loghavi, Sa A. Wang, Yuanqing Yan, Ken Furudate, Ken Furudate, J. Matthews, L. Little, C. Gumbs, Jianhua Zhang, Xingzhi Song, Erika J. Thompson, K. Patel, C. Bueso-Ramos, C. Dinardo, F. Ravandi, E. Jabbour, M. Andreeff, J. Cortes, K. Bhalla, G. Garcia-Manero, H. Kantarjian, M. Konopleva, Daisuke Nakada, N. Navin, N. Beerenwinkel, N. Beerenwinkel, P. Futreal, Koichi Takahashi   +37 more
semanticscholar   +1 more source

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

Haematologica, 2012
Background The hypocellular variant of acute myeloid leukemia accounts for less than 10% of all cases of adult acute myeloid leukemia. It is defined by having less than 20 percent of cellular bone marrow in a biopsy at presentation.
Aref Al-Kali, Sergej Konoplev, Erpei Lin, Tapan Kadia, Stefan Faderl, Farhad Ravandi, Mohamad Ayoubi, Mark Brandt, Jorge E. Cortes, Hagop Kantarjian, Gautam Borthakur   +10 more
doaj   +1 more source

Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia

Haematologica, 2012
The recent identification of DNMT3A mutations in de novo acute myeloid leukemia prompted us to determine their frequency, patterns and clinical impact in a cohort of 98 patients with either therapy-related or secondary acute myeloid leukemia developing ...
Isabella Fried, Claudia Bodner, Monika M. Pichler, Karin Lind, Christine Beham-Schmid, Franz Quehenberger, Wolfgang R. Sperr, Werner Linkesch, Heinz Sill, Albert Wölfler   +9 more
doaj   +1 more source

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations

Haematologica, 2014
Somatic mutations of TET2, IDH1, and IDH2 have been described in myelodysplastic syndrome. The impact of these mutations on outcome of myelodysplastic syndrome and their progression to secondary acute myeloid leukemia remains unclear.
Tung-Liang Lin, Yasunobu Nagata, Hsiao-Wen Kao, Masashi Sanada, Yusuke Okuno, Chein-Fuang Huang, Der-Cherng Liang, Ming-Chung Kuo, Chang-Liang Lai, En-Hui Lee, Yu-Shu Shih, Hiroko Tanaka, Yuichi Shiraishi, Kenichi Chiba, Tung-Huei Lin, Jin-Hou Wu, Satoru Miyano, Seishi Ogawa, Lee-Yung Shih   +18 more
doaj   +1 more source

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant

American Journal of Hematology, Volume 98, Issue 1, Page 159-165, January 2023., 2023
Donor stem cell product undergoes CD34 stem cell selection. CD34 positive stem cells are used for transplantation. Pathogen‐ and leukemia‐specific T‐cells are manufactured from CD34 negative fraction and infused prophylactically 21 days after transplant.
David J. Gottlieb, Gaurav Sutrave, Wei Jiang, Selmir Avdic, Janine A. Street, Renee Simms, Leighton E. Clancy, Vicki Antonenas, Brian S. Gloss, Caroline Bateman, David C. Bishop, Kenneth P. Micklethwaite, Emily Blyth   +12 more
wiley   +1 more source

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Blood, 2009
Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and ...
J. Vardiman, J. Thiele, D. Arber, R. Brunning, M. Borowitz, A. Porwit, N. Harris, M. L. Le Beau, E. Hellström-Lindberg, A. Tefferi, C. Bloomfield   +10 more
semanticscholar   +1 more source